February 2024 – Maven Hemp, a leading player in the CBD industry, has officially rebranded as Maven Bioscience, marking its expanded focus into the field of pharmaceutical medicine and clinical testing. The company, previously known for its hemp-derived products, is now positioning itself as a global leader in precision medicine.
“We are not just a CBD company,” CEO and Founder, Zev Barnett explained. “We have worked, and continue to work, with top doctors and researchers from around the world to develop the best products for you.”
The name change reflects Maven Bioscience’s growing involvement in personalized healthcare. The company is pioneering products tailored to individual DNA profiles- with their groundbreaking DNA-matched formulas. These personalized treatments utilize data from either Endo-DNA genetic testing kits or customers’ existing genetic data from popular services such as 23andMe or AncestryDNA.
By analyzing an individual’s unique genetic profile, Maven Bioscience aims to offer more effective, personalized treatments that deliver optimal results. The move signals the company’s commitment to innovation in the burgeoning field of precision medicine, ensuring that their products meet the needs of consumers in the most targeted way possible.
With this shift, Maven Bioscience is carving out a distinctive niche in the healthcare landscape, blending the power of genetics with pharmaceutical expertise.
